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Abstract Studies of human patellar and Achilles tendons
have shown that primary tendon fibroblasts (tenocytes) not
only have the capacity to produce acetylcholine (ACh) but
also express muscarinic ACh receptors (mAChRs) through
which ACh can exert its effects. In patients with tendinop-
athy (chronic tendon pain) with tendinosis, the tendon tissue
is characterised by hypercellularity and angiogenesis, both
of which might be influenced by ACh. In this study, we have
tested the hypothesis that ACh increases the proliferation
rate of tenocytes through mAChR stimulation and have
examined whether this mechanism operates via the extracel-
lular activation of the epidermal growth factor receptor
(EGFR), as shown in other fibroblastic cells. By use of
primary human tendon cell cultures, we identified cells
expressing vimentin, tenomodulin and scleraxis and found
that these cells also contained enzymes related to ACh
synthesis and release (choline acetyltransferase and vesic-
ular acetylcholine transporter). The cells furthermore
expressed mAChRs of several subtypes. Exogenously ad-
ministered ACh stimulated proliferation and increased the
viability of tenocytes in vitro. When the cells were ex-
posed to atropine (an mAChR antagonist) or the EGFR
inhibitor AG1478, the proliferative effect of ACh de-
creased. Western blot revealed increased phosphorylation,
after ACh stimulation, for both EGFR and the
extracellular-signal-regulated kinases 1 and 2. Given that
tenocytes have been shown to produce ACh and express
mAChRs, this study provides evidence of a possible auto-
crine loop that might contribute to the hypercellularity
seen in tendinosis tendon tissue.
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Introduction
In recent years, increasing attention has been devoted to the
non-neuronal expression of signal substances traditionally
associated with neurons and the potential roles of such
substances in various pathological conditions. Particular
interest has been given to acetylcholine (ACh; Wessler et
al. 2001), a classical neurotransmitter well-known as being
localised in the central and peripheral nervous systems.
Contemporary research has demonstrated that ACh and/or
its synthesising enzyme, choline acetyltransferase (ChAT),
are present in non-neuronal human cells, such as the epithe-
lium of the airways and epidermis, endothelial and muscle
cells and various immune cells (Wessler et al. 2001;
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Kawashima and Fujii 2003). A physiological role of non-
neuronal ACh might explain the widespread presence of
ACh receptors, such as muscarinic receptors (mAChRs), in
tissues not innervated by cholinergic neurons (Wessler et al.
1998). Recently, we have demonstrated that mAChRs of
subtype M2 (M2Rs) are expressed in blood vessels, nerves
and primary fibroblastic cells (tenocytes) in both Achilles
(Bjur et al. 2008) and patellar (Danielson et al. 2006) ten-
dons of man, whereas cholinergic innervation is scarce or
absent. The M2Rs are particularly abundant in tendons
afflicted by tendinosis (Danielson et al. 2006, 2007; Bjur
et al. 2008). Tendinosis frequently underlies tendinopathy, a
clinical condition defined by chronic tendon pain and im-
paired function, and is characterised by a series of histo-
pathological tissue changes (Khan et al. 1999), including
tenocyte proliferation and angiogenesis. The above obser-
vations have led to the hypothesis that ACh plays a role in
the development of tendinosis, since the stimulation of ACh
receptors in other tissues has previously been shown to
stimulate angiogenesis (Jacobi et al. 2002), modulate pe-
ripheral nociception (Vogelsang et al. 1995; Wess et al.
2003) and promote the proliferation of liver myofibroblasts
(Oben et al. 2003). Furthermore, tenocytes in vivo have
been shown to produce a variety of signal substances tradi-
tionally associated with neurons, especially in tendinosis
(for a review, see Danielson 2009). A striking finding in
this regard is the suggested increased production and release
of ACh in tendinosis tissue, as evidenced by a higher ex-
pression of ChAT and the vesicular ACh transporter
(VAChT) in tenocytes (Danielson et al. 2006, 2007; Bjur
et al. 2008).
As is well-known, G-protein coupled receptors (GPCRs),
to which mAChRs belong, can transduce mitogenic signals
leading to proliferation (New and Wong 2007) and evidence
has suggested that an ACh stimulus can result in the prolifer-
ation of fibroblast-like cells via these receptors (Matthiesen et
al. 2006, 2007). In fibroblasts, proliferation is typically medi-
ated by classical mitogen-activated protein kinases (MAPK),
namely extracellular-signal-regulated kinases 1 and 2 (ERK1/
2; Matthiesen et al. 2007). As has also been shown in a variety
of cell types, the stimulation of GPCR can result in the trans-
activation of the epidermal growth factor receptor (EGFR),
leading to the activation of ERK1/2 (New and Wong 2007;
Xie et al. 2009). In some cells, the GPCR-EGFR transmission
appears to be independent of extracellular ligands (relying on
cytoplasmic mechanisms), whereas in other cell types, cell-
surface-bound pro-ligands are processed and released to the
extracellular matrix by metalloproteinases (MMPs; Kraus et
al. 2003; Rozengurt 2007). These ligands subsequently bind
to and stimulate the EGFR.
The role that mAChRs might play in the modulation of
human tendon cell behaviour is unknown. Furthermore,
whether primary Achilles tendon cell cultures maintain their
expression of mAChRs in vitro or retain their capacity for
ACh production is also unknown. Therefore, in this study,
we have examined the presence of mAChRs and the expres-
sion of the synthesising enzyme ChAT and of VAChT in
primary Achilles tendon cell cultures. Moreover, given that
tenocyte proliferation is a prominent and early feature of
tendinosis and that the effect of ACh on tenocyte prolifera-
tion has not previously been studied, we have also examined




These studies were approved by the Regional Ethical Re-
view Board in Umeå and were performed according to the
principles of the Declaration of Helsinki. Written informed
consent was received from all participants.
Human tendon cell culture
Biopsies were isolated and cultured as previously described
(Backman et al. 2011). Briefly, tendon tissue biopsies from
the lateral mid-portion of the Achilles tendon of healthy
donors were enzymatically digested and the cells were cul-
tured in D-MEM supplemented with 10% fetal bovine se-
rum (FBS; Invitrogen, Grand Island, N.Y., USA; code no.
16000), 1% pen-strep (Invitrogen; code no. 15140) and
0.2%L-glutamine (Invitrogen; code no. 25030) at 37°C in
a humidified atmosphere of 5% CO2.
Experimental conditions
The cells used in this study were in passages 3–6 to ensure a
similar phenotype. All experiments were performed under
serum-starved condition of 1%, a condition in which the
cells had a healthy appearance and a steady proliferation
rate. The serum-starved condition was initiated 24 h before
the start of an experiment.
Cell-signalling experiments
The cells were seeded in cell culture plates (BD Bioscience;
BD Falcon, Bedford, Mass., USA; code no. 353004) at a
density of 275,000 cells/plate and incubated under serum-
starved conditions as described under “Experimental
conditions”. The cells were then pre-treated with either
the EGFR inhibitor, AG1478 (0.8 μM; Calbiochem,
Darmstadt, Germany; code no. 658548), the metallopro-
teinase inhibitor, GM6001 (8 μM; Calbiochem; code no.
364206) or the muscarinic receptor antagonist, atropine
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(10−5M; Sigma, Saint Louis, Mo., USA; code no.
A0132) for 30 min. Following this, the cells were
stimulated with ACh (10−6M; Sigma; code no. A2661)
or the vehicle (dimethylsuphoxide) for an additional
30 min. A further control without treatment was also
included. To determine the levels of phosphorylated
(phospho-)ERK1/2 and phospho-EGFR, Western blot
analysis was performed (for details, see below).
Immunocytochemistry
Antibodies directed towards ChAT (1:50; Chemico, Teme-
cula, Calif., USA; code no AB144P), M2R (1:100; Chem-
ico; code no. AB5166), M3R (1:50; Novus Biologiocals,
Littleton, Colo., USA; code no. NLS5259), M4R (1:50;
Novus Biologiocals; code no. NLS220), M5R (1:50; Novus
Biologiocals; code no. NLS1334), VAChT (1:25; Santa
Cruz, Calif., USA; code no. sc-7716), tenomodulin (1:100;
Santa Cruz; code no. sc-49325), vimentin (1:100; Dako,
Glostrup, Denmark; code no. M0725), collagen I (1:100;
Abcam, Cambridge, UK; code no. ab34710), collagen III
(1:100; Abcam; code no. ab7778), scleraxis (1:25; Abcam;
code no. ab58655), alpha-smooth muscle actin (1:100;
Abcam; code no. ab5694) or connexin 43 (1:25; Santa Cruz;
code no. sc-59949) were used. Cells (1.5×104/well) were
seeded on 8-well chamber slides (BD Falcon; code
no. 354118) and allowed to adhere overnight before being
fixed for 5 min in 2% paraformaldehyde in 0.1 M phosphate
buffer (pH7.4) and subsequently washed four times in
phosphate-buffered saline (PBS) before being blocked in
swine (for primary polyclonal antibodies raised in rabbit,
i.e., the antibodies towards M2R, M3R, M4R, M5R, alpha-
smooth muscle actin, scleraxis, collagen I and collagen III),
donkey (for polyclonal goat-antibodies, i.e., antibodies to-
wards ChAT, VAChT and tenomodulin) or rabbit (for the
monoclonal mouse-antibody towards connexin 43) serum
for 15 min. This was followed by incubation with the
primary antibody for 60 min at 37°C or at 4°C overnight.
After being washed four times, an additional blocking step
was performed before incubation with the secondary antibody,
a tetramethylrhodamine isothiocyanate (TRITC)-conjugated
swine anti-rabbit IgG (Dako; Copenhagen, Denmark; code
no. R0156), fluorescein isothiocyanate (FITC)-conjugated
donkey anti-goat IgG (Jackson Immunoresearch; West Grove,
Pa., USA; code no. 705-095-147) or a TRITC-conjugated
rabbit anti-mouse (Dako; code no. R0270) for 30 min at
37°C. When double-staining with vimentin or tenomodulin
was carried out, incubation with the secondary antibody was
followed by four washes in PBS before a blocking step in
normal rabbit or donkey serum for 15 min. The primary
antibody was incubated with the cells for 60 min at 37°C,
followed by an additional four washes in PBS and a blocking
step in normal (rabbit, donkey) serum for 15 min. After
incubation with the secondary antibody, namely a
TRITC-conjugated rabbit anti-mouse IgG (Dako; code
no. R0270) or FITC-conjugated donkey anti-goat IgG
(Jackson Immunoresearch; code no. 705-095-147), the
cells were washed four times in PBS and mounted with
Vectashield Hard Set Medium with 4,6-diamidino-2-phe-
nylindole (DAPI; Vector Laboratories; Burlingame, Calif.,
USA; code no. H-1500).
Expression of M4R in tenocytes was also confirmed on
tissue sections from biopsies of normal healthy tendon tissue
by using immunohistochemistry according to a previously
used protocol (Bjur et al. 2008).
Control staining was performed by the substitution of the
primary antibody with PBS. A Zeiss Axioskop 2 Plus
microscope equipped for epifluorescence and an Olympus
DP70 digital camera was used for analysis.
Western blot
Cells were lysed in a buffer consisting of 150 mM sodium
chloride, 1% Triton, 0.5% sodium deoxycholate, 0.1% so-
dium dodecyl sulphate (SDS), 50 mM TRIS, pH8.0, freshly
supplemented with a protease inhibitor cocktail at a dilution
of 1:200 (Sigma; code no. P1860). Protein concentration
was determined by using the Protein Assay Dye Reagent
Concentrate (Bio-Rad, Hercules, Calif., USA; code no.
500–0006) with bovine serum albumin (BSA; Sigma; code
no. A9647) as a standard. Total protein (20–40 μg) from
each sample or the M2R peptide, used as a positive control
(Chemico; code no. Ab5166), was diluted in a Laemmli
sample buffer (Bio-Rad; code no. 161–0737) and boiled
for 5 min before being loaded and separated on an SDS-
polyacrylamide gel and then transferred to a polyvinylidene
difluoride membrane (Santa Cruz; code no. sc-3723). Pon-
ceau S staining (0.1% Ponceau red, 1% acetic acid diluted in
MilliQ water) confirmed successful transfer before the stain-
ing procedure. Membranes were blocked in 5% non-fat milk
at room temperature for 1 h before incubation with the
primary antibodies. The antibody towards phospho-ERK1/
2 (Thr202, Tyr204) was used at a dilution of 1:2000 (Cell
signal, Danvers, Mass., USA; code no. 4370). According to
the manufacturer, this antibody does not cross-react with the
phosphorylation residues of JNK/SAPK or p38 MAP
kinases. The antibody towards phospho-EGFR was used at
a dilution of 1:1000 (Cell signal; code no. 3777) and,
according to the manufacturer, it might weakly cross-react
with other tyrosine-phosphorylated proteins. The antibody
towards M2R, which is reported by the manufacturer not to
exhibit any cross-reactivity with other muscarinic receptors,
was used at a dilution of 1:1000 (Chemico; code no.
AB5166). The antibody towards M4R was used at a dilution
of 1:500 (Santa Cruz; code no. sc-9109), the antibody to-
wards scleraxis at a dilution of 1:1000 (Abcam; code no.
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ab58655) and the antibody towards beta (β)-actin at a dilu-
tion of 1:2000 (Cell Signal; code no. 4967). All primary
antibodies were raised in rabbit and immunostaining was
performed overnight at 4°C. The membranes were then
washed and incubated with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit secondary antibody, at a dilution
of 1:2000 (Cell Signal; code no. 7074) for 1 h at room
temperature. Band detection was performed by using chemi-
luminescent HRP substrate (GE Healthcare, Little Chalfont,
Buckinghamshire, UK; code no. RPN2132) for 5 min prior
to visualisation on high performance chemiluminescence
film (GE Healthcare; code no. 28-9068-38).
To confirm equal protein loading, the membranes were
stripped with a Western blot stripping buffer (Thermo Sci-
entific, Rockford, Ill., USA; code no. 21059) and re-probed
for β-actin expression.
Cell viability
Crystal violet dye was used to measure cell viability as
previously described (Backman et al. 2011). Briefly,
1.5×105 cells/well were seeded in a 6-well plate and allowed
to adhere overnight before serum starvation. Cells were
washed in PBS to remove non-adherent cells prior to fixa-
tion in 1% glutaraldehyde for 30 min. After additional
washes in PBS, the adherent cells were stained with 0.1%
crystal violet (Sigma; code no. C3886), washed in water, air-
dried and then permeabilised in 30% methanol and 10%
acetic acid. The absorbance was read at 590 nm in a 96-
well plate format. Experiments were performed in triplicate.
Cell proliferation assay with 5-bromo-2′-deoxy-uridine
The manufacturer’s instructions were followed (Roche Ap-
plied Science, Mannheim, Germany; code no. 11299964001).
Briefly, 1.5×104 cells/well on an 8-well chamber slide (BD
Fig. 1 Immunocytochemical staining of primary cultures of human
Achilles tendon cells. Nuclei are stained with 4,6-diamidino-2-phenyl-
indole (DAPI; blue). a Most cells are positive for scleraxis (red,
tetramethylrhodamine isothiocyanate [TRITC]), a key regulator of
tenocyte differentiation. Inset Western blot showing a positive band
for scleraxis corresponding to the predicted size of 22 kDa; β-actin is
shown as a reference. b Cells showing immunoreaction for tenomodulin
(green, fluorescein isothiocyanate [FITC]), a glycoprotein predominantly
expressed in tendons and ligaments. x235 (a) and x185 (b)
Fig. 2 Immunocytochemical staining (red, TRITC) of primary
cultures of human Achilles tendon cells with surrounding extra-
cellular matrix components. Immunofluorescence for collagen I
(a) shows that this protein is abundantly expressed in the cul-
tures, whereas, as expected, collagen III (b) is only sparsely
seen. The cells additionally show positive immunoreaction for
connexin 43 (c), a gap junction protein known to be present in
networks of tendon cells in vivo. The cells are negatively stained
for alpha-smooth muscle actin (d). Nuclei are stained with DAPI
(blue). ×120
468 Cell Tissue Res (2013) 351:465–475
Falcon; code no. 354118) were pre-labelled with 5-bromo-2′-
deoxy-uridine (BrdU) for 120 min at 37°C in a humidified
atmosphere of 5% CO2. This was followed by fixation in a
fixative solution (250mMglycine, 100 ml ethanol, pH2.0) for
20 min at 20°C. Following fixation, the cells were covered
with a monoclonal BrdU antibody for 30 min at 37°C, before
being incubated with anti-mouse-Ig towards alkaline
phosphate for an additional 30 min at 37°C. Finally,
the cells were covered in 4.3 mM nitroblue tetrazolium
and 3.3 mM 5-bromo-4-chloro-3-indolyl-phosphate di-
luted in substrate solution (100 mM TRIS-HCl,
100 mM NaCl, 50 mM MgCl2, pH9.5) and then
mounted in Vectashield HardSet Medium with DAPI
(Vector Laboratories; code no. H-1500). The percentage
of BrdU-positive cells was determined. Experiments
were performed in triplicate.
Reverse transcription with quantitative polymerase chain
reaction
As previously described (Backman et al. 2011), total RNA
was isolated by using an RNeasy kit (Qiagen, Hilden,
Germany; code no. 74106) and then 1 μg of this RNA
was reversed-transcribed into cDNA by using a High
Capacity cDNA Reverse Transcription kit (Applied Bio-
systems [ABI], Warrington, Cheshire, UK; code no.
4368813). Quantitative polymerase chain reaction
(qPCR) was performed by using a TaqMan fast universal
Fig. 3 Cultured human Achilles tendon cells immunopositive (green,
FITC; some marked with arrows) for the acetylcholine (ACh)-synthe-
sising enzyme choline acetyltransferase (ChAT). DAPI staining dem-
onstrates nuclei (blue). ×390
Fig. 4 Cultured human Achilles tenocyte visualised by using immu-
nocytochemistry. a The cell is immunopositive for the ACh-
synthesising enzyme ChAT (green, FITC). b The same cell stained
with DAPI to demonstrate the nucleus (blue) and immunolabelled for
M2R (red, TRITC; arrows). c Digitally merged image of a and b. ×570
Fig. 5 Western blots for M2R (a) and M4R (b) on cultured and lysed
human primary Achilles tendon cells. Immunopositive bands are pres-
ent at the expected molecular weights. β-Actin is shown as a reference.
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PCR master mix (ABI; code no. 4352042) and probes for
M2R (ABI; code no. Hs00265208), M3R (ABI; code
no. Hs00265216), M4R (ABI; code no. Hs00265219),
M5R (ABI; code no. Hs00255278) and scleraxis (ABI;
code no. Hs03054634). Each sample, run in duplicate,
contained the probe (20×), master mix (2×), 20 ng sample
and nuclease-free water to give a final volume of 10 μl for
each reaction. Amplification was conducted under the
following conditions: after 20 s of denaturation at 95°C,
the amplification was carried out for 1 s at 95°C for
denaturation and 20 s at 60°C for annealing/extension in
an ViiA7 instrument. The expression level was determined
relative to the endogenous control, β-actin (ABI; code no.
4333762F).
Statistics
Data were statistically analysed by using PASW Statistics
18 (18.0.0; SPSS, Chicago, Ill., USA). One-way analysis of
variance (ANOVA), followed by the Bonferroni post-hoc
test, was applied. All results were successfully reproduced at
least once. Significance was predetermined at P<0.05.
Results
Phenotyping of cells
The vast majority of cells in the primary cultures were
immunopositive for vimentin, scleraxis (Fig. 1a) and
tenomodulin (Fig. 1b) in the passages and serum concen-
trations used for experiments, thereby indicating a fibroblas-
tic phenotype (tenocytes), as previously described for this
model (Backman et al. 2011). The presence of scleraxis
protein was also confirmed by using Western blot (Fig. 1a,
inset) and the presence of scleraxis mRNA was confirmed
by qPCR. Production of collagen I and also an extremely
low expression of collagen III were further found (Fig. 2a,
b). In addition, cells with myofibroblastic characteristics
could also be excluded, as all cultured cells were negative
for alpha-smooth muscle actin staining in the passages and
serum concentrations used for the experiments (Fig. 2d).
Cells were positively immunostained for connexin 43
(Fig. 2c). Connexin 43 is the main gap junction protein
expected to be found in tendon cells and is known to create
functional linkages among networks of tendon cells in vivo
(McNeilly et al. 1996).
ChAT, VAChT and muscarinic receptor expression
in cultured tendon cells
Most of the cultured human tendon cells were found to
express clear immunoreactivity for ChAT (Figs. 3, 4a) and
VAChT. For the muscarinic receptors, positive immunore-
action on cells was seen for all the studied receptors, includ-
ing, as previously reported for tenocytes in tissue sections
(Danielson et al. 2006, 2007; Bjur et al. 2008), M2R
(Fig. 4b) and, in particular, M4R, which was expressed in
a majority of the cells. In many cases, the same cells
expressed both enzymes related to the synthesis/release of
Fig. 6 Quantitative polymerase chain reaction (qPCR) was used to
study the presence of mRNA for various muscarinic receptor
subtypes. The abundance of mRNA for the various subtypes
was compared with that of M4R, which was set to 100%. The
results show that mRNA for all the studied subtypes is present.
The expression of M1R mRNA is significantly lower than that of
M4R and M5R mRNA. The differences in expression between
M2R and M4R mRNA (P=0.07) and between M3R and M4R
mRNA (P=0.05) were close to significant (error bars standard
deviation). **P≤0.01. One-way analysis of variance (ANOVA)
with the Bonferroni post hoc test, based on triplicates in the
experiment
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ACh and the muscarinic receptors (e.g. Fig. 4c). The pres-
ence of M4R on human tenocytes in tissue sections was
confirmed by immunohistochemistry.
Given earlier results that M2R expression was found in
human tenocytes in tissue sections (Danielson et al. 2006,
2007; Bjur et al. 2008) and that M4R was the subtype with
the highest expression in tendon cell cultures, Western blots
were performed for these two subtypes to confirm their
presence. Western blots for M2R displayed one major band
at 80 kDa in lysates of cultured tendon cells (Fig. 5a). These
results were in accordance with results from a positive
control of purified M2R protein (not shown). Western blots
for M4R displayed a band at 74 kDa corresponding to the
expected size (Fig. 5b).
Expression of M1R, M2R, M3R, M4R and M5R mRNA
was also confirmed to be present in the cells by qPCR
(Fig. 6). M1R mRNAwas expressed at a significantly lower
level than both M4R (P≤0.01) and M5R (P≤0.01) mRNA. A
trend for the higher expression of M4R mRNA was also
noted in comparison with both M2R (P=0.07) and M3R
(P=0.05) mRNA.
Effects of ACh
Exogenously administered ACh significantly increased the
number of viable tendon cells after 36 h of incubation as
seen by crystal violet staining (P<0.01; one-way ANOVA
with the Bonferroni post-hoc test) and this effect was effec-
tively blocked by simultaneous incubation with the musca-
rinic ACh receptor antagonist atropine (Fig. 7).
The percentage of proliferating (BrdU-positive) tendon
cells in cultures after incubation with ACh was significantly
increased (doubled) after 24 h compared with the controls
(P<0.01) but also with cells incubated with atropine
(P<0.05) or the EGFR-blocker AG1478 (P<0.05; Fig. 8;
one-way ANOVA with the Bonferroni post-hoc test).
Western blot analysis revealed that the administration of
ACh resulted in the phosphorylation (i.e. activation) of both
EGFR and ERK1/2 in the cultured cells. This activation
peaked after 20–30 min for EGFR and after 30–45 min for
ERK1/2 (Fig. 9a).
The ERK1/2 phosphorylation induced by incubation
with ACh was effectively blocked in the presence of the
muscarinic receptor antagonist, atropine (Fig. 9b). In
addition, inhibition of either EGFR or MMP with their
specific blockers (AG1478 and GM6001, respectively)
decreased the phosphorylation of ERK1/2 (Fig. 9b).
Discussion
The present study shows that human Achilles tenocytes
express enzymes related to ACh synthesis/release (ChAT and
VAChT) and mAChRs in vitro, findings previously shown for
these cells in vivo, especially in tendinosis (Danielson et al.
2006, 2007; Bjur et al. 2008). Furthermore, we demonstrate
that these cells are encouraged, when exposed to ACh, to
proliferate via mAChR stimulation and subsequently the acti-
vation of EGFR and ERK1/2.
Previous reports have shown that the effects of mAChR
activation include fibroblast proliferation (Matthiesen et al.
2006; Profita et al. 2009), mediated through the activation of
the ERK1/2 pathway (Matthiesen et al. 2007). Other studies
have shown that the stimulation of these receptors on fibro-
blasts increases collagen synthesis in the lungs (Haag et al.
2008) as a part of tissue remodelling in response to chronic
inflammation (Jeffery 2001). In human Achilles tenocytes,
we have, in the present study, observed that, after 24 h, the
number of cells in the S-phase of the cell cycle (BrdU-
positive) is significantly higher in the ACh-exposed cells
and also that, after an additional 12 h, the number of viable
cells is significantly increased as a result. Collagen synthesis
has not been quantified in this study but this would surely be
Fig. 7 Analysis of viable tendon cells in human primary cultures after
36 h of incubation with 10−6M acetylcholine (ACh), without ACh
(Control) and with ACh and the muscarinic ACh receptor blocker
atropine (ACh + Atropine; the concentration of atropine being 10−5
M) measured by absorbance (590 nm) of crystal violet staining. The
significant increase in viable cells seen after incubation with ACh is
effectively blocked with atropine. Cells were seeded at a density of
1.5×105 cells/well in 6-well plates (error bars standard deviation).
**P<0.01 for ACh against both Control and ACh + Atropine. One-
way ANOVAwith the Bonferroni post hoc test, based on triplicates in
the experiment
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an interesting next step, as tendinosis is characterised by
increased collagen type III content, which is also seen in the
early stages of tendon healing (Maffulli et al. 2000).
The cultured tendon cells of the present model have been
shown to retain a fibroblastic phenotype in the early pas-
sages used for the experiments here, by the immunofluores-
cence for vimentin (typical of mesechyme-derived cells,
such as fibroblasts; Rufai et al. 1992) and tenomodulin (a
specific marker for tenocytes; Docheva et al. 2005; Jelinsky
et al. 2010), a finding confirmed in an earlier study of our
model (Backman et al. 2011). Tenomodulin is a type II
transmembrane glycoprotein that is highly expressed in
tendons and ligaments and it has been reported to be posi-
tively regulated by scleraxis, which is a transcription factor
that also regulates the expression of type I collagen, thus
being a key transcription factor in tenocyte differentiation
(Shukunami et al. 2006; Lejard et al. 2007; Jelinsky et al.
2010). Scleraxis has been observed at both the protein and
the mRNA levels in the cells of this study. The proliferative
effect of ACh on these fibroblastic cells has been found to
be mAChR-dependent and to lead to EGFR and ERK1/2
activation. An overview of the proposed pathway is pre-
sented in Fig. 10.
The specific MMP responsible for cleaving the pro-
ligand to a mature EGFR ligand has not been defined in this
study. However, we have observed a tendency towards
decreased ERK1/2 phosphorylation in response to the
broad-spectrum MMP inhibitor GM6001, which has
Fig. 9 a Western blot showing phosphorylated EGFR (P-EGFR) and
extracellular-signal-regulated kinases 1 and 2 (P-ERK1/2) in cultured
human Achilles tendon cells at various time points after incubation
with ACh (10−6M). Exposure to ACh resulted in phosphorylation (i.e.
activation) of both EGFR and ERK1/2 in the cultured cells; this
activation peaked after 20–30 min for EGFR and 30–45 min for
ERK1/2. β-Actin is shown as a reference. b Western blot showing
phosphorylated ERK1/2 (P-ERK1/2) in cultured human Achilles ten-
don cells after 45 min of incubation in pure ACh (10−6M), ACh and
the muscarinic ACh receptor antagonist atropine (+Atropine), ACh and
a metalloproteinase (MMP) antagonist (+GM6001), ACh and an
EGFR antagonist (+AG1478), regular media (Control) or dimethyl-
suphoxide (DMSO). ERK1/2 activation by ACh is effectively blocked
when incubated simultaneously with atropine. Moreover, inhibition of
either EGFR or MMP reduces the phosphorylation of ERK1/2. β-Actin
is shown as a reference
Fig. 8 Mean fraction of proliferating (BrdU-positive) tendon cells in
human primary cultures after 24 h of incubation with ACh (10−6M),
without ACh (Control), with ACh and the muscarinic receptor inhib-
itor atropine (10−5M) and with ACh and the epidermal growth factor
receptor (EGFR) inhibitor AG1478 (0.8 μM). A statistically significant
increase can be seen in the percentage of proliferating cells after
incubation with ACh compared with the control (**P<0.01) and com-
pared with incubation with the inhibitors (*P<0.05). No significant
difference can be found between the treatments with atropine and
AG1478 or between either of the inhibitors and the control. Cells were
seeded at a density of 1.5×104 cells/well in 8-well chamber slides
(error bars standard deviation). One-way ANOVA test with the Bon-
ferroni post hoc test, based on triplicates in the experiment
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MMP-1 as its primary target and MMP-2, −3, −8 and −9 as
secondary targets. The finding that the inhibitory effect is
not more dramatic might be attributable to the involvement
of other MMPs that are not affected by GM6001. For
example, in colon cancer cells, Xie et al. (2009) have shown
that ACh induces proliferation involving MMP-1, MMP-7
and MMP-10, in turn, leading to EGFR activation, which
can be abolished with the muscarinic inhibitor atropine and
that the stimulation of MMP-7 mimics the actions of ACh.
Another possible agent is the tumor necrosis factor alpha
(TNFα)-converting enzyme (TACE or ADAM17). This en-
zyme is known to cleave TNFα but has also been found to
be the only metalloprotinease that efficiently cleaves trans-
forming growth factor-alpha (TGFα), another EGFR ligand
(Hinkle et al. 2003). GPCR stimulation in colonocytes leads
to the cleavage and release of the mature TGFα, which binds
to, and phosphorylates, EGFR (Koon et al. 2004).
The targeting of mAChRs is frequently used in the clin-
ical setting to abolish unwanted effects of ACh and
mAChRs have been proposed as potential targets in several
diseases, such as chronic obstructive pulmonary disease in
which the inhibition of mAChRs can delay the decline in
lung function (Vincken et al. 2002; Anzueto et al. 2005).
The mAChR family can be divided into the “odd-num-
bered” and the “even-numbered” receptors. The “even-num-
bered” receptors M2R and M4R couple via Gi and Go α
subunits (Caulfield and Birdsall 1998). In lung fibroblasts,
M2R has been found to be the most prominent mAChR and
the regulation of fibroblast proliferative rate has been shown
to correlate best with modulation via M2R (Matthiesen et al.
2006). In this study, we have confirmed the presence of
M2R protein and mRNA in cultured human tenocytes, find-
ings previously shown for tenocytes in tissue sections from
both patellar (Danielson et al. 2006) and Achilles (Bjur et al.
2008) tendons in man. However, the expression of the other
known mAChRs has not previously been examined in hu-
man tendons. In this study, we have also investigated M3R,
M4R and M5R, with M4R clearly being the most abundantly
expressed receptor in the in vitro setting. The expression of
M4R has, in the present study, also been confirmed for
tenocytes in tissue sections. This study has not investigated
the possible expression or role of nicotinic ACh receptors,
which is a drawback. Nevertheless, since the proliferative
effect of ACh in this study is abolished with atropine, we
have confirmed that proliferation takes place preferably
through muscarinic stimulation and not nicotinic receptor
stimulation.
The verification of ACh production by human tenocytes
is based on the expression of ChAT and VAChT and not on a
measurement of the ACh molecule itself. This is of course a
limitation of this study, although, as has been repeatedly
reported, the expression of ChAT and VAChT is correlated
to ACh production. ChAT catalyses the synthesis of ACh
from choline and acetyl-CoA (Tuček 1982, 1988) and
VAChT is known then to shuttle ACh to vesicles in the
nerve terminal (Eiden 1998). Over-expression of VAChT is
related to an increased ACh release (Prado et al. 2002). All
in all, the present study supports the existence of a cholin-
ergic autocrine loop in tenocytes (Forsgren et al. 2009a,
2009b), ACh produced by the cells themselves being able
to stimulate the proliferation of the same cells through the
activation of the ERK1/2 system via binding to the mAChRs
on the cell surface. The potential relevance of this phenom-
enon to tendinosis is evident, given that hypercellularity is
such a prominent feature in the histopathology, both at early
and late stages (Khan et al. 1999). Nevertheless, other
possible targets of the ACh produced by tenocytes in tendon
tissue might be receptors found in blood vessel walls or on
sensory nerve fascicles (Danielson et al. 2006; Bjur et al.
2008). These receptor sites are also of interest, since ACh
has well-known vascular and pain-modulating effects
(Vogelsang et al. 1995; Dussor et al. 2004), tendinosis also
being characterised by vascular changes and chronic pain
(Khan et al. 1999; Alfredson and Ohberg 2005; Cook et al.
2005).
In summary, based on the results of the present study and
on those of our previous investigations (Danielson et al.
2006, 2007; Bjur et al. 2008), we propose the following.
Human tenocytes, harbouring the capability to produce
ACh, increase this production during tendinosis
Fig. 10 Representation of the proposed cellular pathways involved in
the acetylcholine (ACh)-induced proliferation of human tendon cells.
ACh stimulates membrane-bound muscarinic ACh receptors (mAChR)
that in turn activate matrix metalloproteinases (MMP) to cleave a cell-
surface-associated epidermal growth factor receptor ligand (EGFR
ligand). The ligand then binds to EGFR, which in turn increases cell
proliferation through the phosphorylation of the mitogen-activated
protein kinases, extracellular-signal-regulated kinases 1 and 2 (ERK1/
2). The results of the present study identify a potential role for each of
these steps (see Figs. 8, 9). Artwork by G. Andersson
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development. Via an autocrine loop, the ACh produced by
tenocytes stimulates mAChRs on the cell surface, which in
their turn increase ERK1/2 phosphorylation through the
activation of EGFR and contribute to the increased cell
proliferation (Fig. 10) and the tenocyte hypercellularity seen
in tendinosis. In an early stage of tendinosis, hypercellular-
ity might be a part of a healing or adaptive response but, in
the chronic stage, excessive tenocyte proliferation could be
detrimental to tendon structure and function. The non-
neuronal cholinergic system of tendon tissue is thus a pos-
sible target for future modulation of these processes in
tendinosis.
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